Depression

New England CEPAC

Major depressive disorder (MDD) is a common and debilitating condition; on an annual basis, it is estimated that nearly 14 million Americans will have at least one episode of MDD.  While definitions of so-called “treatment-resistant” depression vary, this generally refers to patients with persistent depression after attempted management with two or more medications.

Interventions of interest, 2019 review: Esketamine (Janssen)

Interventions of interest, 2011 review: Repetitive transcranial magnetic stimulation, electroconvulsive therapy, vagus nerve stimulation, and cognitive-behavioral therapy/interpersonal therapy

ASSOCIATED MEETING & MATERIALS

Midwest CEPAC
May 23, 2018 9am- 5pm CT

Hyatt Regency O’Hare
9300 Bryn Mawr Avenue
Rosemont, IL 60018

The Midwest CEPAC will convene to review evidence on esketamine as a therapy for treatment-resistant depression. The Council will also review a report on siponimod for treatment of secondary progressive MS during this meeting.

Key Dates

Associated Materials

10/10/2018 – 10/25/2018
Open Input Period

10/30/2018
Draft Scoping Document

10/30/2018
Stakeholder List

10/30/2018 – 11/19/2018
Public Comments

11/29/2018
Revised Scoping Document

01/14/2019
Research Protocol

02/05/2019
Model Analysis Plan

03/21/2019
Draft Voting Questions

03/21/2019
Draft Evidence Report

03/21/2019 – 04/17/2019
Public Comments

05/09/2019
Evidence Report

05/09/2019
Revised Voting Questions

05/09/2019
Response to Comments

05/23/2019
Meeting Agenda

05/23/2019
Evidence Presentation

06/20/2019
Final Evidence Report and Meeting Summary

06/20/2019
Report-at-a-Glance


ASSOCIATED MEETING & MATERIALS

New England CEPAC
December 9, 2011 10am-4pm

Brown University, Providence, RI

Key Dates

Associated Materials

12/09/2011

12/09/2011

Public comments received on the Draft Evidence Report.